Expanding Large Molecule Capabilities: Teva#8217;s Latest Acquisition
By Business Review Editor
Pharma Deals Review: Vol 2008 Issue 93 (Table of Contents)
Published: 1 Mar-2008
DOI: 10.3833/pdr.v2008.i93.207 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
The desire of generics companies to diversify into the biologics arena has been demonstrated in the recent US$400 M acquisition of CoGenesys by the Israeli generics giant, Teva Pharmaceutical Industries...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS